查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1484941

2024 年披衣菌感染披衣菌 (CT) 和淋病奈瑟菌 (NG) 檢測全球市場報告

Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Global Market Report 2024
出版日期: | 出版商: The Business Research Company | 英文 175 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

披衣菌感染衣原體（CT）和淋病奈瑟菌（NG）檢測市場規模預計在未來幾年將快速成長。 2028年，將以11.0%的複合年成長率成長至30億美元。預計未來的成長是由於遠端醫療和遠端醫療服務的使用增加、個人化醫療方法的採用、就地檢驗的擴大以及人口健康管理策略的實施。在此期間預計的主要趨勢包括擴大快速就地檢驗能力、引入個人化檢測方法、開發多疾病檢測平台以及擴大以地區為基礎的檢測和推廣計劃。

性行為感染（STI）的日益普及預計將在短期內推動披衣菌感染衣原體（CT）和淋病（NG）檢測市場的擴張。性行為感染是透過性接觸傳播的細菌、病毒和寄生蟲感染疾病，由於性教育不足、性活動活性化、社會恥辱和接觸障礙等因素，性傳染感染呈上升趨勢。 CT和NG檢測在性傳染感染的檢測和管理中發揮重要作用，有助於早期診斷、治療和感染預防。例如，根據世界衛生組織（WHO）2023年7月報告，全球每天有超過100萬人新增感染性傳染感染，每年新增感染者達3.74億，佔估計的四分之一。性傳染感染。因此，性行為感染的流行凸顯了 CTNG 檢測市場的成長軌跡。

披衣菌感染衣原體 (CT) 和淋病奈瑟菌 (NG) 檢測市場的主要參與者正在優先考慮開拓創新的檢測解決方案，以滿足對抗性傳播感染的準確且可擴展的檢測方法日益成長的需求。 BD COR MX/PX 系統就是這類解決方案之一，它是一種高通量感染疾病分子診斷平台。這種複雜的測試設備旨在快速分析大量檢體中的感染疾病。 BD COR MX/PX 系統由 Becton Dickinson 於 2022 年 5 月推出，簡化了實驗室處理大量傳染病檢查（包括 CT 和 NG 檢測）的工作流程。該平台使用機器人技術和軟體演算法來自動化整個測試過程，從而可能提高效率並減少測試結果等待時間。顯著的特點包括自動化、高通量能力、雙 DNA 靶向以及模組化和可擴展的設計。

目錄

第1章執行摘要

第2章 市場特點

第3章 市場趨勢與策略

第4章宏觀經濟情景

  • 高通膨對市場的影響
  • 烏克蘭與俄羅斯戰爭對市場的影響
  • COVID-19 對市場的影響

第5章世界市場規模與成長

  • 全球披衣菌感染衣原體（CT）和淋病奈瑟菌（NG）檢測市場：促進因素和限制因素
    • 市場促進因素
    • 市場限制因素
  • 全球披衣菌感染衣原體 (CT) 和淋病奈瑟菌 (NG) 檢測市場表現：規模和成長，2018-2023 年
  • 全球披衣菌感染衣原體 (CT) 和淋病奈瑟菌 (NG) 檢測市場預測：規模和成長，2023-2028 年，2033F

第6章 市場細分

  • 全球披衣菌感染衣原體 (CT) 和淋病奈瑟菌 (NG) 檢測市場：按檢測類型分類的實際和預測，2018-2023、2023-2028F、2033F
  • 實驗室
  • 就地檢驗
  • 全球披衣菌感染衣原體 (CT) 和淋病奈瑟菌 (NG) 檢測市場：按產品分類的表現和預測，2018-2023、2023-2028F、2033F
  • 檢測方法和套件
  • 設備或分析設備
  • 全球披衣菌感染衣原體 (CT) 和淋病奈瑟菌 (NG) 檢測市場：按技術分類的表現和預測，2018-2023、2023-2028F、2033F
  • 恒溫核酸增幅技術
  • 聚合酵素鏈鎖反應
  • 免疫診斷
  • 其他技術
  • 全球披衣菌感染衣原體 (CT) 和淋病奈瑟菌 (NG) 檢測市場：最終用戶的表現和預測，2018-2023、2023-2028F、2033F
  • 診斷實驗室
  • 醫院和診所
  • 其他最終用戶

第 7 章 區域/國家分析

  • 全球披衣菌感染衣原體 (CT) 和淋病奈瑟菌 (NG) 檢測市場：按地區分類的表現和預測，2018-2023、2023-2028F、2033F
  • 全球披衣菌感染衣原體 (CT) 和淋病奈瑟菌 (NG) 檢測市場：按國家/地區分類的表現和預測，2018-2023、2023-2028F、2033F

第8章亞太市場

第9章 中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章 德國市場

第18章 法國市場

第19章 義大利市場

第20章 西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章加拿大市場

第26章 南美洲市場

第27章 巴西市場

第28章 中東市場

第29章 非洲市場

第30章 競爭格局及公司概況

  • 披衣菌感染衣原體（CT）與淋病（NG）檢測市場：競爭格局
  • 披衣菌感染衣原體 (CT) 和淋病奈瑟菌 (NG) 檢測市場：公司簡介
    • F. Hoffmann-La Roche AG
    • Thermo Fisher Scientific
    • Abbott Laboratories
    • Danaher Corporation
    • Merck KGaA

第31章 其他大型創新企業

  • Siemens Healthineers
  • Becton Dickinson and Company
  • Grifols SA
  • Hologic Inc.
  • PerkinElmer
  • bioMerieux
  • Sysmex Corporation
  • Bio-Rad Laboratories
  • QIAGEN
  • Quidel Corporation
  • DiaSorin
  • Cepheid
  • Seegene Inc.
  • Meridian Bioscience Inc.
  • Sekisui Diagnostics

第32章競爭基準化分析

第 33 章. 競爭對手儀表板

第34章 重大併購

第35章前瞻性與潛力分析

第36章附錄

簡介目錄
Product Code: r17309

Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) testing involves diagnosing sexually transmitted infections (STIs) caused by these bacteria in sexually active individuals, particularly those with multiple partners or engaging in unprotected sexual activity. These tests aim to identify the presence of CT and NG bacteria through various methods such as urine samples, genital area swabs, or blood tests.

The primary testing methods for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are laboratory testing and point-of-care testing. Laboratories are specialized facilities equipped with trained personnel and specialized equipment to conduct CT and NG testing on patient samples. This includes a range of products such as assays, kits, instruments, and analyzers utilizing various technologies such as isothermal nucleic acid amplification technology, polymerase chain reaction, immunodiagnostics, among others. End users of these laboratory services include diagnostic laboratories, hospitals, clinics, and other healthcare facilities.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market research report is one of a series of new reports from The Business Research Company that provides chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market statistics, including chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing industry global market size, regional shares, competitors with a chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market share, detailed chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market segments, market trends and opportunities, and any further data you may need to thrive in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing industry. This chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market size has grown rapidly in recent years. It will grow from $1.79 billion in 2023 to $1.98 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth observed during the historical period can be attributed to several factors, including the emergence of antibiotic resistance, heightened awareness campaigns and educational initiatives, as well as policy changes aimed at addressing the challenges posed by sexually transmitted infections (STIs) such as Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG).

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market size is expected to see rapid growth in the next few years. It will grow to $3.00 billion in 2028 at a compound annual growth rate (CAGR) of 11.0%. The forecasted growth in the upcoming period can be attributed to the increasing utilization of telemedicine and telehealth services, the adoption of personalized medicine approaches, the expansion of point-of-care testing, and the implementation of population health management strategies. Major trends anticipated in this period encompass the broadening of rapid point-of-care testing capabilities, the implementation of personalized testing approaches, the development of multi-disease testing platforms, and the expansion of community-based testing and outreach programs.

The escalating prevalence of sexually transmitted infections (STIs) is anticipated to drive the expansion of the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in the foreseeable future. STIs, resulting from bacterial, viral, or parasitic infections transmitted through sexual contact, are on the rise due to factors such as inadequate sex education, heightened sexual activity, societal stigma, and accessibility barriers. CT and NG testing plays a crucial role in the detection and management of STIs, facilitating early diagnosis, treatment, and prevention of transmission. For instance, as reported by the World Health Organization in July 2023, over 1 million new STIs are contracted daily worldwide, with an estimated 374 million new infections occurring annually, encompassing one in four treatable STIs. Consequently, the escalating prevalence of sexually transmitted infections underscores the growth trajectory of the CTNG testing market.

Key players in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are prioritizing the development of innovative testing solutions to address the growing need for accurate and scalable testing methods to combat STIs. One such solution is the BD COR MX/PX System, a high-throughput infectious disease molecular diagnostic platform. This sophisticated laboratory instrument is designed to rapidly analyze large numbers of samples for infectious agents. Launched by Becton Dickinson and Company in May 2022, the BD COR MX/PX System streamlines workflow in labs processing numerous infectious disease tests, including CT and NG testing. The platform automates the entire testing process using robotics and software algorithms, enhancing efficiency and potentially reducing wait times for test results. Notable features include automation, high-throughput capability, dual DNA targets, and a modular and scalable design.

In September 2021, F. Hoffmann-La Roche AG bolstered its molecular diagnostics portfolio by acquiring TIB Molbiol, a Germany-based biotechnology company, for an undisclosed sum. This strategic acquisition enhances Roche's capabilities in molecular diagnostics, particularly in infectious diseases, and broadens its range of tests for existing and emerging pathogens. TIB Molbiol's Lightmix Kit 480 HT CT/NG, a CT/NG testing solution, strengthens Roche's offerings in the STI testing segment, enabling the company to provide innovative diagnostic solutions and improve patient outcomes in the field of infectious diseases.

Major companies operating in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers, Becton Dickinson and Company, Grifols SA, Hologic Inc., PerkinElmer, bioMerieux, Sysmex Corporation, Bio-Rad Laboratories, QIAGEN, Quidel Corporation, DiaSorin, Cepheid, Seegene Inc., Meridian Bioscience Inc., Sekisui Diagnostics, J. Mitra & Co. Pvt. Ltd., Atlas Medical, Hardy Diagnostics, Molbio Diagnostics Pvt. Ltd., NG Biotech

North America was the largest region in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in 2023. The regions covered in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market includes revenues earned by entities by providing services such as diagnostic testing, sample collection, laboratory analysis, and confidential counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market also includes the sale of sample collection kits, control materials, laboratory equipment, and software solutions. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

  • Including: 1) By Test Type: Laboratory; Point Of Care Testing
  • 2) By Product: Assays And Kits; Instruments Or Analyzers
  • 3) By Technology: Isothermal Nucleic Acid Amplification Technology; Polymerase Chain Reaction; Immunodiagnostics
  • 4) By End User: Diagnostic Laboratories; Hospitals And Clinics
  • Covering: F. Hoffmann-La Roche AG; Thermo Fisher Scientific; Abbott Laboratories; Danaher Corporation; Merck KGaA

Table of Contents

1. Executive Summary

2. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Characteristics

3. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Trends And Strategies

4. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Size and Growth

  • 5.1. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Segmentation

  • 6.1. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Laboratory
  • Point Of Care Testing
  • 6.2. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Assays And Kits
  • Instruments Or Analyzers
  • 6.3. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Isothermal Nucleic Acid Amplification Technology
  • Polymerase Chain Reaction
  • Immunodiagnostics
  • Other Technologies
  • 6.4. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Diagnostic Laboratories
  • Hospitals And Clinics
  • Other End Users

7. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Regional And Country Analysis

  • 7.1. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 8.1. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 9.1. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 9.2. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 10.1. India Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 11.1. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 11.2. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 12.1. Australia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 13.1. Indonesia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 14.1. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 14.2. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 15.1. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 15.2. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 16.1. UK Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 17.1. Germany Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 18.1. France Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 19.1. Italy Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 20.1. Spain Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 21.1. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 21.2. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 22.1. Russia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 23.1. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 23.2. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 24.1. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 24.2. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 25.1. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 25.2. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 26.1. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 26.2. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 27.1. Brazil Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 28.1. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 28.2. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 29.1. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 29.2. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Competitive Landscape And Company Profiles

  • 30.1. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Competitive Landscape
  • 30.2. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche AG
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Thermo Fisher Scientific
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Abbott Laboratories
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Danaher Corporation
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Merck KGaA
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Other Major And Innovative Companies

  • 31.1. Siemens Healthineers
  • 31.2. Becton Dickinson and Company
  • 31.3. Grifols SA
  • 31.4. Hologic Inc.
  • 31.5. PerkinElmer
  • 31.6. bioMerieux
  • 31.7. Sysmex Corporation
  • 31.8. Bio-Rad Laboratories
  • 31.9. QIAGEN
  • 31.10. Quidel Corporation
  • 31.11. DiaSorin
  • 31.12. Cepheid
  • 31.13. Seegene Inc.
  • 31.14. Meridian Bioscience Inc.
  • 31.15. Sekisui Diagnostics

32. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Competitive Benchmarking

33. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

35. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Future Outlook and Potential Analysis

  • 35.1 Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer